BACKGROUND AND PURPOSE: HPV associated Head and Neck Squamous Cell Carcinoma (HNSCC) represents a distinct subgroup of HNSCC characterized by a favorable prognosis and a distinct molecular biology. Previous data from the randomized DAHANCA 5 trial indicated that HPV positive tumors did not benefit from hypoxic modifications by Nimorazole during radiotherapy, whereas a significant benefit was observed in the HPV negative tumors. However, more studies have demonstrated equal frequencies of hypoxic tumors among HPV-positive and HPV-negative tumors. The aim of the present study was to determine radiosensitivity, the impact of hypoxia and the effect of Nimorazole in HPV positive and HPV negative cell lines. MATERIALS AND METHOD: The used cell lines were: UDSCC2, UMSCC47 and UPCISCC90 (HPV positive) and FaDuDD, UTSCC33 and UTSCC5 (HPV negative). Cells were cultured under normoxic or hypoxic conditions, and gene expression levels of previously established hypoxia induced genes were assessed by qPCR. Cells were irradiated with various doses under normoxia, hypoxia or hypoxia +1mM Nimorazole, and the clonogenic survival was determined. RESULTS: The HPV positive and HPV negative cell lines exhibited similar patterns of upregulation of hypoxia induced genes in response to hypoxia. The HPV positive cell lines were up to 2.4 times more radiation sensitive than HPV negative cell lines. However, all HPV positive cells displayed the same response to hypoxia in radiosensitivity, with an OER in the range 2.3-2.9, and a sensitizer effect of Nimorazole of 1.13-1.29, similar to HPV negative cells. CONCLUSIONS: Although HPV positive cells had a markedly higher radiosensitivity compared to HPV negative cells, they displayed the same relative radioresistance under hypoxia and the same relative sensitizer effect of Nimorazole. The clinical observation that HPV positive patients do not seem to benefit from Nimorazole treatment is not due to inherent differences in hypoxia sensitivity or response to Nimorazole, but can be accounted for by the overall higher radiosensitivity of HPV positive cells.
BACKGROUND AND PURPOSE: HPV associated Head and Neck Squamous Cell Carcinoma (HNSCC) represents a distinct subgroup of HNSCC characterized by a favorable prognosis and a distinct molecular biology. Previous data from the randomized DAHANCA 5 trial indicated that HPV positive tumors did not benefit from hypoxic modifications by Nimorazole during radiotherapy, whereas a significant benefit was observed in the HPV negative tumors. However, more studies have demonstrated equal frequencies of hypoxic tumors among HPV-positive and HPV-negative tumors. The aim of the present study was to determine radiosensitivity, the impact of hypoxia and the effect of Nimorazole in HPV positive and HPV negative cell lines. MATERIALS AND METHOD: The used cell lines were: UDSCC2, UMSCC47 and UPCISCC90 (HPV positive) and FaDuDD, UTSCC33 and UTSCC5 (HPV negative). Cells were cultured under normoxic or hypoxic conditions, and gene expression levels of previously established hypoxia induced genes were assessed by qPCR. Cells were irradiated with various doses under normoxia, hypoxia or hypoxia +1mM Nimorazole, and the clonogenic survival was determined. RESULTS: The HPV positive and HPV negative cell lines exhibited similar patterns of upregulation of hypoxia induced genes in response to hypoxia. The HPV positive cell lines were up to 2.4 times more radiation sensitive than HPV negative cell lines. However, all HPV positive cells displayed the same response to hypoxia in radiosensitivity, with an OER in the range 2.3-2.9, and a sensitizer effect of Nimorazole of 1.13-1.29, similar to HPV negative cells. CONCLUSIONS: Although HPV positive cells had a markedly higher radiosensitivity compared to HPV negative cells, they displayed the same relative radioresistance under hypoxia and the same relative sensitizer effect of Nimorazole. The clinical observation that HPV positive patients do not seem to benefit from Nimorazole treatment is not due to inherent differences in hypoxia sensitivity or response to Nimorazole, but can be accounted for by the overall higher radiosensitivity of HPV positive cells.
Authors: Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi Journal: Clin Cancer Res Date: 2019-02-27 Impact factor: 12.531
Authors: Vanessa Vanderdys; Amir Allak; Fadila Guessous; Mouadh Benamar; Paul W Read; Mark J Jameson; Tarek Abbas Journal: Mol Cancer Ther Date: 2017-08-24 Impact factor: 6.261
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Karin Hoppe-Seyler; Felicitas Bossler; Claudia Lohrey; Julia Bulkescher; Frank Rösl; Lars Jansen; Arnulf Mayer; Peter Vaupel; Matthias Dürst; Felix Hoppe-Seyler Journal: Proc Natl Acad Sci U S A Date: 2017-01-23 Impact factor: 11.205
Authors: Tomasz Kolenda; Weronika Przybyła; Marta Kapałczyńska; Anna Teresiak; Maria Zajączkowska; Renata Bliźniak; Katarzyna M Lamperska Journal: Rep Pract Oncol Radiother Date: 2018-03-17
Authors: Erina Vlashi; Allen M Chen; Sabrina Boyrie; Garrett Yu; Andrea Nguyen; Philip A Brower; Clayton B Hess; Frank Pajonk Journal: Int J Radiat Oncol Biol Phys Date: 2016-01-14 Impact factor: 7.038